Apheresis as emerging treatment option in severe early onset preeclampsia.
Apheresis
Dextrane sulfate adsorption
HELP apheresis
Lipoprotein apheresis
Lipoproteins
Preeclampsia
sFlt-1
Journal
Atherosclerosis. Supplements
ISSN: 1878-5050
Titre abrégé: Atheroscler Suppl
Pays: Netherlands
ID NLM: 100973461
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
11
12
2019
pubmed:
11
12
2019
medline:
26
5
2020
Statut:
ppublish
Résumé
Based on an early suggestion by Winkler et al. 2003 and a subsequent successful study by Wang et al. 2006 using lipid apheresis (LA) in 9 patients with preeclampsia to prolong pregnancies, the use of apheresis as therapeutic option in severe early onset preeclampsia has received increasing attention. Further studies using different LA systems also prolonged pregnancy and have been published in the last few years. Albeit using different LA systems and relying on different working hypothesis, all studies demonstrated a promising stabilisation against the disease's progression. Overall time from hospitalisation to the need for mandatory delivery was longer for those patients receiving apheresis compared to historical or matched control patients not receiving apheresis. These data will be reviewed and different hypotheses about the beneficial mechanism of action of apheresis will be discussed. Since up to now there is no curative treatment for preeclampsia other than observation and delivery, future work shall be encouraged.
Identifiants
pubmed: 31818451
pii: S1567-5688(19)30051-0
doi: 10.1016/j.atherosclerosissup.2019.08.028
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-67Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.